Margarida Maia, PhD,  science writer—

The first patients received doses of an oral thin-film formulation of montelukast in a clinical trial testing the treatment’s potential for Parkinson’s disease. The placebo-controlled MONTPARK trial will test how well a high dose of Montelukast VersaFilm, a proprietary formulation being developed by IntelGenx, can slow the progression…

The presence of salt or a molecular crowd may make it more likely for the alpha-synuclein protein, which forms toxic clumps in the brains of people with Parkinson’s disease, to aggregate, or build up, into droplets, according to computer simulations run by researchers in India. Understanding how alpha-synuclein behaves,…

People with Parkinson’s disease are nearly twice as likely to experience delirium during hospital stays as hospitalized older adults without the neurodegenerative disease, according to a study from Newcastle University. Data showed that delirium, which often goes undocumented in Parkinson’s, was reported in as many as two-thirds of…

NeuroOne has begun a limited U.S. commercial launch of its OneRF Ablation System, a device that can be used for mapping and targeting brain areas with abnormal neuronal activity to treat a range of neurological conditions such as Parkinson’s disease. The company said it’s rolling out the…

BioVie is planning to launch in late summer a Phase 2b clinical trial of NE3107, its investigational anti-inflammatory small molecule, as an initial and stand-alone treatment for Parkinson’s disease, the company announced in a release. The trial aims to recruit between 100 and 150 newly diagnosed Parkinson’s…

Monte Rosa Therapeutics is running preclinical studies testing MRT-8102, an orally available molecular glue degrader that targets NEK7, a protein needed to set off a type of inflammatory response involved in diseases including Parkinson’s. The studies are a key step in the process of seeking approval for clinical…

An antibody that targets a naturally occurring modified form of alpha-synuclein, a protein that forms into toxic clumps in the brain of people with Parkinson’s, delays its buildup and spread in vivo in a mouse model of the disease. This modified form of nitrated alpha-synuclein is being explored by…

People exposed to high levels of the pesticides and herbicides often used in farming have up to a 36% greater risk of Parkinson’s disease than those living in regions with the lowest exposure, a U.S. study reports. The work, to be presented at the American Academy of Neurology (AAN)…

Amneal Pharmaceuticals has resubmitted its application for IPX203, an investigational extended-release oral formulation of carbidopa and levodopa for treating Parkinson’s disease. The move follows a request by the U.S. Food and Drug Administration (FDA) in July 2023 for more information on the safety of IPX203’s carbidopa component…

Vyalev, a brand name for AbbVie’s ABBV-951 (foslevodopa/foscarbidopa), is now available in Canada as a continuous, subcutaneous (under-the-skin) infusion treatment for people with advanced Parkinson’s disease and motor symptoms that cannot be well controlled with oral medications. “AbbVie is proud to deliver the first new treatment…